Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 26 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 11230542

    Inhibitors of integrated stress response pathway

    PRAXIS BIOTECH LLC · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  2. US 11229679

    Compositions for treating heart disease by inhibiting the action of mAKAPβ

    Anchored RSK3 Inhibitors, LLC · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  3. US 11230537

    Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  4. US 11225514

    Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)

    The Regents of the University of California · Granted Jan 18, 2022 · Expires Jan 13, 2042

    granted

  5. US 11225477

    Inhibitors of influenza virus replication, application methods and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Jan 18, 2022 · Expires Jan 13, 2042

    granted

  6. US 11225469

    Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 18, 2022 · Expires Jan 13, 2042

    granted

  7. US 11220524

    Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

    Prelude Therapeutics, Incorporated · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted

  8. US 11220509

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted

  9. US 11220501

    Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor

    Revolution Medicines, Inc. · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted

  10. US 11220479

    Glucosylceramide synthase inhibitors and therapeutic methods using the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted

  11. US 11220486

    Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted

  12. US 11214574

    Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

    Prelude Therapeutics, Incorporated · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted

  13. US 11213513

    Compositions and methods for promoting hair growth with Mpc1 inhibitors

    The Regents of the University of California · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted

  14. US 11214567

    Small molecule inhibitors of MYC and uses thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted

  15. US 11208413

    Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

    ALMAG DISCOVERY LIMITED · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted

  16. US 11207314

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted

  17. US 11208432

    Inhibitors of glucocorticoid receptor

    ORIC PHARMACEUTICALS, INC. · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted

  18. US 11208405

    Pyrrole derivatives as PLK1 inhibitors

    SENTINEL ONCOLOGY LIMITED · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted

  19. US 11208416

    Selective inhibitors of protein arginine methytransterase 5 (PRMT5)

    Prelude Therapeutics, Incorporated · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted

  20. US 11203574

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted

  21. US 11203602

    Thioester prodrugs of macrocycles as inhibitors of histone deacetylases

    OnKure, Inc. · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted

  22. US 11203600

    Kinase inhibitors and uses thereof

    DENALI THERAPEUTICS INC. · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted

  23. US 11198691

    N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

  24. US 11198694

    HDAC6 inhibitors, with improved solubility and their uses

    Universität Regensburg · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.